Xenetic Biosciences Inc (XBIO) Stock Price, Quote & News

Company Profile

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carc...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 778 7720

Website: www.xeneticbio.com

Address:

945 Concord Street, Framingham, United States

JovianJest Dec. 27 at 12:56 PM

$XBIO Positioning reflects caution while awaiting confirmable progress; capital allocation choices will face heightened scrutiny — stable fundamentals would matter more than macro swings. Durability will separate winners from speculation.

0 · Reply

The_Real_G Dec. 26 at 10:40 PM

$XBIO All time lows. Should pump to 3-4$ easily soon.

0 · Reply

smallcapswing Dec. 21 at 6:38 PM

$XBIO

0 · Reply

aafetygod Dec. 20 at 1:20 PM

$XBIO $LRHC i'm planning to buy XBIO after my LRHC play. My PT1 is 2.75 and PT2 is 3.45. Haha... I just hope it stays put until I get in... doubt it though, right?

0 · Reply

frontiere Dec. 17 at 9:02 PM

$XBIO Xenetic ref=$1.96 — started Long here — nanocap, way under cash now after Oct 2025 Canaccord underwritten raise of 735k shs at $6.12 — est $7.8m cash now w 2.3m shs outs =$3.3 cash per sh.👍 Dec 2025 Corp deck https://www.xeneticbio.com/news-media/presentations A bit fuzzy re catalysts in that deck. But good the company cares to update this. 👍At the low price level, just waiting for any PR. 👍Lindy chart.

0 · Reply

Love_To_Learn Dec. 16 at 11:54 PM

$XBIO NEED YOUR ASSISTANCE SHORTLY

0 · Reply

Estebanvel Dec. 16 at 6:45 PM

$XBIO what happened today?

0 · Reply

Meri7 Dec. 16 at 6:05 PM

$XBIO and this???

0 · Reply

Meri7 Dec. 16 at 5:26 PM

$XBIO is this not you hahah @TreasureBois

0 · Reply

Meri7 Dec. 16 at 5:18 PM

$VVOS $XBIO is below book value, looks interesting

0 · Reply

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Nov 19, 2025, 8:45 AM EST - 5 weeks ago

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Nov 13, 2025, 8:45 AM EST - 6 weeks ago

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Oct 10, 2025, 9:30 AM EDT - 2 months ago

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

Aug 13, 2025, 8:00 AM EDT - 4 months ago

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 9:00 AM EDT - 5 months ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Jul 23, 2025, 8:30 AM EDT - 5 months ago

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Jul 8, 2025, 9:00 AM EDT - 6 months ago

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

May 14, 2025, 8:05 AM EDT - 8 months ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 9, 2025, 9:15 AM EDT - 9 months ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

$Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma$

Mar 26, 2025, 9:00 AM EDT - 9 months ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

Mar 19, 2025, 8:05 AM EDT - 10 months ago

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

Mar 13, 2025, 8:30 AM EDT - 10 months ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

Feb 27, 2025, 9:15 AM EST - 10 months ago

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

Dec 16, 2024, 9:00 AM EST - 1 year ago

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Dec 5, 2024, 8:45 AM EST - 1 year ago

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

Nov 21, 2024, 8:30 AM EST - 1 year ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

Nov 13, 2024, 8:30 AM EST - 1 year ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 9:00 AM EST - 1 year ago

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

Nov 7, 2024, 9:00 AM EST - 1 year ago

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Oct 22, 2024, 8:45 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Oct 17, 2024, 8:45 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

May 10, 2024, 8:30 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Mar 22, 2024, 8:00 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

Jan 17, 2024, 9:00 AM EST - 2 years ago

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Nov 10, 2023, 8:35 AM EST - 2 years ago

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

Oct 11, 2023, 9:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

Sep 5, 2023, 8:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 11, 2023, 8:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

Jul 5, 2023, 8:45 AM EDT - 2 years ago

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series

May 12, 2023, 12:30 PM EDT - 2 years ago

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

May 11, 2023, 4:30 PM EDT - 2 years ago

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 4, 2023, 8:35 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D.

May 3, 2023, 8:35 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Mar 23, 2023, 7:35 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update

Mar 16, 2023, 11:00 AM EDT - 3 years ago

JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences

Mar 16, 2023, 8:05 AM EDT - 3 years ago

Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event

Jan 17, 2023, 8:05 AM EST - 3 years ago

Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy

Jan 5, 2023, 8:05 AM EST - 3 years ago

Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event

Nov 16, 2022, 8:35 AM EST - 3 years ago

Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform

Nov 10, 2022, 7:05 AM EST - 3 years ago

Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 11, 2022, 8:05 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

VNRX

Oct 4, 2022, 8:00 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board

Sep 7, 2022, 8:05 AM EDT - 3 years ago

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 12, 2022, 8:00 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 2, 2022, 8:05 AM EDT - 3 years ago

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

VNRX

Jul 7, 2022, 9:00 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study

JovianJest Dec. 27 at 12:56 PM

0 · Reply

The_Real_G Dec. 26 at 10:40 PM

$XBIO All time lows. Should pump to 3-4$ easily soon.

0 · Reply

smallcapswing Dec. 21 at 6:38 PM

$XBIO

0 · Reply

aafetygod Dec. 20 at 1:20 PM

$XBIO $LRHC i'm planning to buy XBIO after my LRHC play. My PT1 is 2.75 and PT2 is 3.45. Haha... I just hope it stays put until I get in... doubt it though, right?

0 · Reply

frontiere Dec. 17 at 9:02 PM

0 · Reply

Love_To_Learn Dec. 16 at 11:54 PM

$XBIO NEED YOUR ASSISTANCE SHORTLY

0 · Reply

Estebanvel Dec. 16 at 6:45 PM

$XBIO what happened today?

0 · Reply

Meri7 Dec. 16 at 6:05 PM

$XBIO and this???

0 · Reply

Meri7 Dec. 16 at 5:26 PM

$XBIO is this not you hahah @TreasureBois

0 · Reply

Meri7 Dec. 16 at 5:18 PM

$VVOS $XBIO is below book value, looks interesting

0 · Reply

Meri7 Dec. 16 at 2:27 PM

$XBIO 👀

0 · Reply

Meri7 Dec. 15 at 11:08 PM

$XBIO @TreasureBois and @LukePumpwalker posted at the same time twice, looks like two fake pumpers to me

0 · Reply

Zurb88 Dec. 12 at 10:59 AM

$XBIO

0 · Reply

topstockalerts Nov. 19 at 9:31 PM

After Hours Top Gainers $CRNC $FCUV $ODD $XBIO $WLACU

0 · Reply

Swayz99 Nov. 19 at 2:02 PM

11/19 WL -> $EPWK (leader w/ news, ww break of PM highs for scalp plays) $SGBX (slow grind PM, needs vol but ww for scalps) $FRGT (cheaper priced, but these have been getting the attention) $XBIO (backburner) $SUUN (backburner, needs vol) Another absolute dud in PM with small caps. Not seeing anything at all and not looking to force any trades until we see some momentum return. Will be watching scanners at open, but not expecting much. Trade the plan. Happy Huntin'!

0 · Reply

DARKP00L Nov. 19 at 1:51 PM

$XBIO 08:47 on Nov. 19 2025 Xenetic Biosciences Executes 4-Month Extension Of Collaboration With Institute Investigator At Scripps Research To Advance Development Of R&D Program Evaluating Combination Of Systemic Dnase I And CAR T-Cell Therapies #tradeideas

0 · Reply

Stock_Catcher Nov. 19 at 1:49 PM

$XBIO Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

0 · Reply

jimsmits Nov. 7 at 7:46 PM

$XBIO not like this to have pump and then dump and raise

0 · Reply

Market Cap	5.04M
Revenue (ttm)	2.50M
Net Income (ttm)	-3.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-158.40%
Debt to Equity Ratio	0.00

Volume	54,800
Avg Vol	61,750
Day's Range	N/A - N/A
Shares Out	2.29M
Stochastic %K	36%
Beta	2.40
Analysts	Strong Buy
Price Target	$40.00